Log in to your Inderes Free account to see all free content on this page.
Annexin Pharmaceuticals
0.331
SEK
+3.44 %
Less than 1K followers
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
+3.44%
-29.08%
-21.71%
-24.16%
-35.06%
+30.51%
-30.78%
-49.7%
-89.65%
Annexin Pharmaceuticals is a biotechnology company with development in the Annexin A5 area. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for the treatment of patients with damage and inflammation in the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment and production of Annexin A5. The company was founded in 2014 and is based in Stockholm.
Read moreMarket cap
231.55M SEK
Turnover
20.94K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
14.5.
2025
Interim report Q1'25
15.5.
2025
General meeting '25
17.7.
2025
Interim report Q2'25
ShowingAll content types
Annexin Pharmaceuticals AB: BioStock: Annexin confirms promising results and strengthens financial position
Database lock completed in Annexin's Phase 2a study in RVO. Data confirms promising results – providing strong support for continued development of the drug candidate ANXV
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio